Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2008-08-28 Board/Management Inform…
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Other Report or Announcement
Board/Management Information Classification · 95% confidence The document is a short regulatory filing (1696 chars) dated 28/08/2008 from XTL BIOPHARMACEUTICALS LTD. It is filed under 'Other Report or Announcement' and explicitly states that it contains two items: '1) Notification of Extraordinary General Meetings' and '2) Further Changes to Board Composition.' 1. 'Notification of Extraordinary General Meetings' relates to shareholder meetings, which could suggest AGM-R or DVA, but the document itself is an announcement, not the results or the presentation. 2. 'Further Changes to Board Composition' directly maps to the definition of Board/Management Information (MANG). Given the 'MENU VS MEAL' rule, since this is a brief announcement referencing attached or contained information about board changes and meeting notifications, and it doesn't fit perfectly into the specific meeting result (DVA) or AGM presentation (AGM-R) categories, the most accurate classification for the content described ('Changes to Board Composition') is MANG. However, because it is a general regulatory announcement referencing multiple items, and MANG is a specific category, MANG is the primary fit for the board change component. If the document were longer and contained the full details, it would be MANG. Since it's a short notice announcing the content, it could potentially be RNS, but MANG is a more specific fit for the core content described ('Changes to Board Composition'). Given the explicit mention of 'Changes to Board Composition,' MANG is the strongest classification.
2008-08-28 English
Board/Management Information 2008
Board/Management Information Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, XTL Biopharmaceuticals Ltd. It announces the convening of two Extraordinary General Meetings (EGMs) and details proposed changes to the board composition, including appointments of new external directors and a resignation. It also mentions remuneration items to be approved at the second EGM. The content focuses on board changes and meeting notices rather than financial results or detailed reports. The document length is 4411 characters, which is relatively short and primarily an announcement. Therefore, it fits best under Board/Management Information (MANG) as it announces changes in the company's board of directors and related meeting notices.
2008-08-27 English
Regulatory Filings 2008
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., pursuant to SEC rules. It includes an exhibit index listing a press release, a notice of extraordinary general meetings, and a proxy form for those meetings. The document length is short (1994 characters), and it primarily serves as a regulatory filing to provide updates and notices rather than containing detailed financial data or full reports. The presence of a proxy form and meeting notice suggests it relates to shareholder meeting materials, but since it is a Form 6-K and includes multiple exhibits without detailed financial statements or management discussion, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2008-08-27 English
Immediate Report
Director's Dealing Classification · 100% confidence The document is a SEC Form 3 filing, which is an initial statement of beneficial ownership of securities by insiders such as directors or officers. It details the ownership of securities by Michael S. Weiss, a director of XTL Biopharmaceuticals Ltd, including options and American Depository Receipts. This type of filing is related to insider transactions and ownership disclosures, which corresponds to Director's Dealing filings. The document is not a financial report, earnings release, or any other type of report but a regulatory filing specifically about insider ownership. Therefore, the correct classification is Director's Dealing (DIRS). The document length and content confirm it is not an announcement or certification but the actual filing of insider ownership information.
2008-08-27 Hebrew (modern)
Immediate Report
Regulatory Filings Classification · 95% confidence The document is an 'Immediate Report' filed under Israeli regulations (Regulation 4 of the Securities Regulations). The key content states: 'Attached hereto is a report on *Initial statement of beneficial ownership of securities* v124972_XTL_Form3_MichaelWeiss_FINAL_isa.pdf'. This indicates the document itself is an announcement about an attached filing, specifically related to insider ownership (Form 3 is typically an initial statement of beneficial ownership). Since the document is short and serves to announce the publication of another specific report (an insider ownership statement), it fits the description of a general regulatory announcement that doesn't fit a more specific category like ER, IR, or 10-K. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general regulatory announcement that isn't a standard financial report or a specific insider trading report (DIRS, which usually details the transaction itself, not just the attachment of the initial statement). However, since the content explicitly mentions 'Initial statement of beneficial ownership of securities' (which relates to insider holdings), and DIRS covers 'Report of personal share transactions by company directors and executives (insider trades)', RNS is the safest general regulatory catch-all when the specific form (like a Form 3) isn't explicitly mapped, although DIRS is closely related. Given the structure is an announcement of an attachment, RPA or RNS applies. Since it is a mandatory filing to the ISA/TASE, RNS (General regulatory announcements) is preferred over RPA (Report Publication Announcement, which is often used for voluntary reports).
2008-08-27 English
Director's Dealing 2008
Director's Dealing
2008-08-26 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.